L
László Sipos
Publications - 3
Citations - 1087
László Sipos is an academic researcher. The author has contributed to research in topics: Procarbazine & Lomustine. The author has an hindex of 3, co-authored 3 publications receiving 946 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Alba A. Brandes,Martin J.B. Taphoorn,Johan M. Kros,Mathilde C.M. Kouwenhoven,Jean-Yves Delattre,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Pim J. French,Winand N.M. Dinjens,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia,Khê Hoang-Xuan +18 more
TL;DR: The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors, and 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/ 19q-deleted tumors.
Journal ArticleDOI
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951
Mathilde C.M. Kouwenhoven,Thierry Gorlia,Johan M. Kros,Ahmed Ibdaih,Alba A. Brandes,Jacolien E.C. Bromberg,Karima Mokhtari,Sjoerd G. van Duinen,Johannes L. Teepen,Pieter Wesseling,Fanny Vandenbos,Wolfgang Grisold,László Sipos,René O. Mirimanoff,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Martin J. van den Bent +17 more
TL;DR: Of all molecular markers analyzed in this study, especially loss of 1p/19q carried prognostic significance, while the others contributed little prognostic value to classical histology.
Journal ArticleDOI
Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).
Martin J. van den Bent,Khê Hoang-Xuan,Alba A. Brandes,Johan M. Kros,Mathilde C.M. Kouwenhoven,Martin J B Taphoorn,Jean-Yves Delattre,Hans J. J. B. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Winand N.M. Dinjens,Pim J. French,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia +18 more
TL;DR: The EORTC Brain Tumor Group conducted a prospective phase III study on adjuvant procarbazine, CCNU and vincristine chemotherapy (PCV) in AOD and long-term follow-up is presented.